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Children with serious chronic illnesses have the poten-
tial for significant bone morbidity, particularly in the
context of disorders with impaired muscle function and
the need for glucocorticoid (GC) treatment. Recently,
studies have shown that vertebral fractures are often the
first sign of osteoporosis in this context. Longitudinal
studies have taught us that vertebral fractures are most
frequent in the first year of GC therapy among children
with GC-treated diseases, that vertebral fractures are
often asymptomatic and thereby go undetected in the
absence of routine monitoring, and that even asympto-
matic vertebral fractures predict an increased risk of
future fractures. Other discrete clinical predictors of
incident vertebral fractures are evident early in the
course of GC therapy, including decreases in spine
BMD Z-scores and increases in body mass index Z-
scores in the first 6 months of GC therapy. Taken
together, these observations highlight that the first year
of GC therapy is a critical period for monitoring in
order to identify bone morbidity in a timely fashion.
Children with risk factors for bone morbidity other than
GC therapy (such as neuromuscular disorders and
immobilization) are also at increased risk for vertebral
and non-vertebral fractures fractures. As such, routine
surveillance for vertebral fractures (for example, with a
lateral spine radiograph) is now considered a key facet
of the bone health evaluation in children with chronic
immobilization or GC-treated diseases.
While some risk factors for osteoporosis will be perma-
nent (such as immobilization arising from disorders such
as cerebral palsy), other children will experience transient
threats to bone health. This is an important distinction,
since children with transient threats have the potential for
vertebral body reshaping, either spontaneously or with
bone-targeted treatment such as bisphosphonate therapy.
Recovery from fracture-induced deformity is growth-
dependent, underscoring the importance of timely diagno-
sis and intervention during childhood in those with limited
potential for spontaneous vertebral body reshaping.
Prevention begins with optimization of conservative
measures, including physical activity, nutrition, treatment
of co-morbid endocrinopathies and aggressive treatment
of the underlying disease using the lowest effective GC
dose. These measures may be insufficient to prevent first-
time fractures in some, raising the need for bone-specific
therapy in line with a secondary prevention approach.
Secondary prevention is predicated upon identification of
early signs of osteoporosis and intervention to prevent dis-
ease progression. Since bone-targeted treatment is typi-
cally reserved for children with overt fragility, careful
monitoring to avoid advanced osteoporosis presentations
is paramount. Bisphosphonates are the most commonly
prescribed agents in children; however, interest in the use
of novel osteo-anabolic therapy is mounting given bone
histomorphometric observations that osteoporosis in chil-
dren with serious chronic illnesses is typically character-
ized by significant reductions in bone turnover.
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